PTEN and prostate carcinoma: In addition to PTEN alterations, alterations of other members of the PI3K signaling pathway are frequent in prostate cancer, involving alterations of PI3KCA (13%), PIK3R1 (6%), NF2 (3%), AKT1 (1.5%), and NF1 (1.5%) [255].